Soliris approved in China for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
Soliris approved in China for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) The approval by the National Medical Products Administration (NMPA) in China was based on results…
FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents Pfizer Inc. (NYSE: PFE) announced today that the…
AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER
AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER Amgen (NASDAQ:AMGN) today announced results from the global Phase 2 DeLLphi-301 study, evaluating tarlatamab, an investigational delta-like ligand 3 (DLL3) targeting…
AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2023
AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2023 Amgen (NASDAQ:AMGN) today announced that it will host a webcasted call for the investment community at 8:00 a.m. ET on Tuesday, Oct. 24, 2023 following the presentation…
Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio
Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio Sanofi has delivered the first medicines from its Global Health Unit’s not-for-profit Impact brand portfolio to the Republic of…
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program Gilead Sciences, Inc. (Nasdaq: GILD) today announced PURPOSE 5, the…
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative…
REGENERON BUILDS ON TOGETHER FOR CHANGE™ INITIATIVE WITH FIVE-YEAR, $5 MILLION COMMITMENT TO FUEL THE STEM TALENT PIPELINE IN NASHVILLE, TN
REGENERON BUILDS ON TOGETHER FOR CHANGE™ INITIATIVE WITH FIVE-YEAR, $5 MILLION COMMITMENT TO FUEL THE STEM TALENT PIPELINE IN NASHVILLE, TN TARRYTOWN, N.Y., Oct. 18, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today…
TOGETHER FOR CHANGE GENOMICS AND EQUITY INITIATIVE LAUNCHED BY A COALITION OF MEHARRY MEDICAL COLLEGE, REGENERON GENETICS CENTER, ASTRAZENECA, NOVO NORDISK, AND ROCHE TO IMPROVE HEALTH OUTCOMES FOR PEOPLE OF AFRICAN ANCESTRY
TOGETHER FOR CHANGE GENOMICS AND EQUITY INITIATIVE LAUNCHED BY A COALITION OF MEHARRY MEDICAL COLLEGE, REGENERON GENETICS CENTER, ASTRAZENECA, NOVO NORDISK, AND ROCHE TO IMPROVE HEALTH OUTCOMES FOR PEOPLE OF…
European Commission Approves ADCETRIS for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD Takeda (TSE:4502/NYSE:TAK) today announced that the European…
Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire
Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire Takeda (TSE:4502/NYSE:TAK) today announced that it agreed with the Irish Revenue Commissioners (“Irish Revenue”) to settle a…
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel in Complex Crohn’s Perianal Fistulas
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas Takeda (TSE:4502/NYSE: TAK) today announced that the Phase 3 ADMIRE-CD II study,…